scispace - formally typeset
X

Xunhao Xiong

Researcher at University of Oklahoma Health Sciences Center

Publications -  11
Citations -  576

Xunhao Xiong is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Cancer cell & Gene silencing. The author has an hindex of 9, co-authored 11 publications receiving 397 citations. Previous affiliations of Xunhao Xiong include University of Oklahoma.

Papers
More filters
Journal ArticleDOI

Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth

TL;DR: It is demonstrated that gold nanoparticles (AuNPs) inhibit proliferation and migration of both PCCs and PSCs by disrupting the bidirectional communication via alteration of the cell secretome through the ER-stress-regulated IRE1-dependent decay pathway (RIDD).
Journal ArticleDOI

MICU1 drives glycolysis and chemoresistance in ovarian cancer

TL;DR: It is demonstrated that the gatekeeper of mitochondrial Ca2+ uptake, Mitochondrial Calcium Uptake 1 (MICU1/CBARA1) drives aerobic glycolysis in ovarian cancer, and a significant correlation between pPDH (inactive form of PDH) expression with poor prognosis is observed.
Journal ArticleDOI

Cystathionine β-synthase regulates endothelial function via protein S-sulfhydration

TL;DR: It is shown that the loss of CBS function in endothelial cells (ECs) leads to a significant down‐regulation of cellular hydrogen sulfide (H2S) by 50% and of glutathione (GSH) by 40%, highlighting the importance of CBS‐mediated protein S‐sulfhydration in maintaining vascular health and function.
Journal ArticleDOI

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.

TL;DR: By depleting stem cell pools and inhibiting key molecular pathways gold nanoparticles sensitize ovarian cancer cells to cisplatin and may be used in combination to inhibit tumor growth and metastasis in ovarian cancer.
Journal ArticleDOI

Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer

TL;DR: In vivo, orally administered PTC-028, as a single agent, exhibits significant antitumor activity comparable with the standard cisplatin/paclitaxel therapy in an orthotopic mouse model of ovarian cancer, demonstrating the potential to be used as an effective therapeutic agent in patients with epithelial ovarian cancer where treatment options are limited.